Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) develops molecular diagnostic tests, with a primary focus on transplant rejection monitoring and additional programs in oncology. Its products and development portfolio includes laboratory-developed tests performed at its own laboratory, research-use-only kits, and… From the company’s description.
Over the twelve months to Jun 30, 2026, Insight Molecular Diagnostics Inc. reported revenue of $1.67M, down 60.8% from a year earlier, and a net loss of $49.36M. Operations used $26.95M in cash. In fiscal 2025, it reported revenue of $4.05M, up 115.6% from fiscal 2024, and a net loss of $50.22M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Insight Molecular Diagnostics Inc. does
In the company’s own words
Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) develops molecular diagnostic tests, with a primary focus on transplant rejection monitoring and additional programs in oncology. Its products and development portfolio includes laboratory-developed tests performed at its own laboratory, research-use-only kits, and clinical in vitro diagnostic kits designed for use by local laboratories. The initial target customers are hospitals, transplant centers and laboratories; physicians and laboratory leaders influence adoption, while researchers use its research products. The GraftAssure family measures donor-derived cell-free DNA: GraftAssureCore is its laboratory-developed test, GraftAssureIQ is a research-use-only kit, and GraftAssureDx is a clinical kit in development. The company also offers oncology assays DetermaIO and DetermaCNI and performs assay development and clinical testing services for life sciences and biotechnology companies. Its laboratory services include a CLIA-certified laboratory in Tennessee and research and development facilities in the United States and Germany. The company reported no segment breakdown; it was incorporated in 2009 and acquired Insight Genetics in 2020 and Chronix Biomedical in 2021. Its website is www.imdxinc.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Chemicals
- Headquarters
- NASHVILLE, TN
- Fiscal year end
- December
- CIK
- 1642380
- SIC
- 2835
Financial performance, year by year
Fiscal 2016–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Insight Molecular Diagnostics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Insight Molecular Diagnostics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Insight Molecular Diagnostics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Insight Molecular Diagnostics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Insight Molecular Diagnostics Inc.'s last four quarterly filings that the numbers alone won't show?”